

REMARKS

The claims are 9-20, with claims 9 and 10 being independent. Claims 1-8 have been cancelled without prejudice or disclaimer. Support for claims 9-20 may be found throughout the specification and in claims 1-8. Further support for claim 9 may be found on page 3, lines 19-35 of the specification. Support for claims 9-20 involving the term "hydrate" may be found on page 4, lines 9-12.

Claims 1, 3 and 8 were rejected under 35 U.S.C. 112, first and/or second paragraphs. Applicants traverse these rejections. Cancellation of claims 1-8 renders these rejections moot, however, Applicants will address the rejections to the extent that they may apply to the pending claims.

The Examiner indicated that previously pending claim 8 was enabled for treatment of anxiety, depression, schizophrenia, and mild cognitive impairment, but not, allegedly, for the other cited diseases/disorders (e.g. obesity). Support for the treatment of obesity (claims 17 and 18) using 5-HT₆ receptor antagonists may be found in Woolley et al. *Neuropharmacology*, Vol. 41: pg 210 (2001) and WO 03/035061 A1.

The Examiner has questioned the use of 5-HT₆ antagonists for the treatment of Alzheimers disease and other cognitive memory disorders. Support for the treatment of Alzheimers disease (claims 19 and 20) and cognitive memory disorders (claims 13 and 14) using 5-HT₆ receptor antagonists may be found in the documents listed in the IDS submitted herewith. Included in these documents is an abstract reporting pre-clinical data for a 5-HT₆ receptor antagonist compound, two citations from ClinicalTrials.org describing clinical studies using a 5-HT₆ receptor antagonist compound in Alzheimers disease and a December 2007 LSE announcement that includes a discussion of the outcome of these two clinical trials.

Applicants submit herewith a new Abstract that provides the generic structure of the compounds of formula (I).


The Examiner has advised that Applicants' IDS filed on March 20, 2006 cannot be fully considered as none of the references were seen in the electronic file. Applicants hereby resubmit the IDS, along with the references, with this response.

In view of the foregoing amendments and remarks, Applicants respectfully submit that the subject application is in condition for allowance. If the Examiner has any

Appln. No.: 10/572,671
Group Art Unit No.: 1624

remaining objections or concerns, the Examiner is respectfully requested to contact Applicants' undersigned attorney to resolve such issues and advance the case to issue.

Respectfully submitted,



Kathryn L. Sieburth
Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090
N:\dmf\cases\pb60516\ROA_1_22_08.doc